Swiss National Bank Has $55.28 Million Holdings in Illumina, Inc. $ILMN

Swiss National Bank raised its position in Illumina, Inc. (NASDAQ:ILMN) by 6.5% in the first quarter, HoldingsChannel reports. The fund owned 448,500 shares of the life sciences company’s stock after purchasing an additional 27,400 shares during the quarter. Swiss National Bank’s holdings in Illumina were worth $55,282,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Empowered Funds LLC boosted its position in shares of Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Illumina during the second quarter worth $621,000. CW Advisors LLC purchased a new position in Illumina in the second quarter worth $275,000. Marshall Wace LLP boosted its holdings in shares of Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after buying an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC raised its position in Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after acquiring an additional 1,748 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the transaction, the chief accounting officer directly owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock worth $155,710,908 over the last three months. 2.90% of the stock is currently owned by insiders.

Illumina Price Performance

ILMN opened at $192.53 on Wednesday. The stock has a market capitalization of $29.13 billion, a P/E ratio of 35.01, a PEG ratio of 2.73 and a beta of 1.47. The stock has a 50-day moving average price of $168.22 and a 200-day moving average price of $144.20. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $196.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts predict that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Sanford C. Bernstein began coverage on shares of Illumina in a research note on Friday, June 26th. They set a “market perform” rating and a $185.00 price target for the company. Canaccord Genuity Group increased their target price on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. TD Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday, July 15th. Finally, Barclays upped their price target on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th. Nine analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $156.88.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.